Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%
Market cap
$13.8B
P/E
34.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

124.50% 153.59% 99.40% 173.67%
Piotroski F-Score
8 5 5 5
ROA
27.45% 13.81% 14.33% 17.86%
ROIC
35.11% 14.31% 15.64% 18.13%
Return on Tangible Assets
105.78% 43.39% 48.31% 61.47%
Average Days of Receivables
101.62 115.33 110.82 100.00
Free Cash Flow per Share
6.31 5.38 5.65 6.87
Free Cash Flow
739.68 644.59 667.65 806.22
Capital Expenditures
128.68 (6.97) (9.76) (12.37)
Other line items
Cash ROIC
27.23% 27.61% 24.89% 31.98%
Accounts Receivable Turnover
3.93 3.73 3.96 4.31
Accounts Payable Turnover
13.84 14.69 15.19 13.83
Inventory Turnover
1.21 1.44 1.62 1.84
Average Days of Payables
29.19 33.34 19.82 29.47
Days of Inventory on Hand
353.10 281.56 218.58 171.17
Tax Rate
(0.20) (0.32) (0.31) (0.29)
Research and Development Expense of Revenue
5.63% 26.23% 25.00% 23.28%
Selling, General and Administrative Expense of Revenue
13.86% 14.83% 14.76% 14.30%
Share Based Compensation of Revenue
3.74% 3.69% 3.81% 3.79%
Interest Coverage
41.53 25.87 26.79 29.41
Operating CF/Net income
1.03 2.06 1.94 1.98
Depreciation/Fixed assets
1.17 1.12 1.31 1.45
Capex/Depreciation
1.54 (0.08) (0.09) (0.10)
Revenue per Share
10.60 11.65 12.77 14.19
Operating CF per Share
5.21 5.44 5.73 6.98
Capex per Share
1.10 (0.06) (0.08) (0.11)
Capex to Sales
(0.10) 0.01 0.01 0.01

Fold the line items

Columns are period end dates